GET DAILY SIGNALSWhy Is Quantum-Si (QSI) Stock Down -8.04% Today?
Key Takeaways
- QSI shares fell roughly 8.04% to about $1.03, extending Friday's steep selloff from a prior close of $1.12.
- The primary catalyst was a fresh analyst downgrade, with Wall Street Zen cutting the stock from "hold" to "sell."
- Secondary pressure came from a broad biotechnology-sector selloff that has hit speculative, pre-revenue life-sciences names hard.
- The decline also reflects profit-taking after a Proteus-driven rally pushed the stock to an 11-month high in mid-October.
- Traders are now watching the upcoming third-quarter earnings report on November 5 and the company's Proteus development milestones.
Opening Summary
Quantum-Si Incorporated (QSI), a Branford, Connecticut-based proteomics technology company that develops single-molecule protein sequencing instruments, extended its losses in Monday's session. The stock fell approximately 8.04% to around $1.03, down from Friday's closing price of $1.12. The decline came on the heels of an already sharp 14.5% drop in the prior session, as a fresh sell-side downgrade compounded a wider pullback across the biotechnology sector.
Analyst Downgrade Adds Selling Pressure
The most direct catalyst for Monday's move was a downgrade from Wall Street Zen, which lowered its rating on QSI from "hold" to "sell." For a speculative, development-stage company whose valuation is largely tied to future product launches, rating changes carry outsized weight, particularly when they follow a rapid price run-up. The downgrade reinforced concerns about execution risk and near-term commercial traction, prompting investors to lock in recent gains.
Broad Biotechnology Sector Selloff
The stock's decline also reflects broader weakness across the biotechnology complex. The Nasdaq Biotechnology Index fell sharply in Friday's session, with a wide range of development-stage and genomics names trading lower. Quantum-Si's shares were among the sector's notable decliners, underscoring how risk appetite toward pre-revenue life-sciences companies has cooled. When sector-wide sentiment deteriorates, high-beta names with limited near-term revenue tend to experience amplified moves.
Profit-Taking After a Proteus-Fueled Rally
The pullback follows a strong rally earlier in October. On October 8, Quantum-Si announced that its next-generation Proteus platform had demonstrated detection of 19 amino acids, one short of the full set of 20 needed for complete protein sequencing. The news propelled the stock higher, and shares climbed to an 11-month high above $1.40 by mid-October. With those gains now partially unwound, Monday's selling reflects a classic giveback of a sentiment-driven spike as momentum cooled.
Market Context and Trading Activity
Trading activity has been notably heavy relative to the stock's typical average volume, consistent with the elevated participation seen during Friday's decline. The move has diverged from the action in broader large-cap benchmarks, which have been comparatively stable, highlighting the stock-specific and sector-specific nature of the selling. Despite the decline, QSI remains above its 50-day and 200-day moving averages, a reminder that it is still trading well off its 52-week lows even as it surrenders its October gains. The stock's elevated beta and meaningful short interest have also contributed to outsized day-to-day volatility.
What Comes Next for QSI
Investors' attention now shifts to Quantum-Si's third-quarter 2026 business update and financial results, scheduled for November 5, 2026. Management commentary on the Proteus commercial launch timeline, which has already been pushed to the second quarter of 2027, will be closely scrutinized. The company has also targeted the demonstration of all 20 standard amino acids by the end of 2026, a milestone that could refocus sentiment. Risks include continued technology and manufacturing execution uncertainty, persistent cash burn, potential future dilution, and a still-weak commercial revenue base. Any further deterioration in biotechnology-sector risk appetite could also keep pressure on the shares.
Trending AI Robots
For traders seeking a more systematic approach to volatile names like QSI, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches tailored to different market environments. Explore the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Momentum Indicator for QSI turns negative, indicating new downward trend
QSI saw its Momentum Indicator move below the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for QSI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 23 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 41 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 160 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 96 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.616) is normal, around the industry mean (4.142). P/E Ratio (-2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement